Status: Recruiting
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Participants needed: 167
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Henlius BiotechUpdated: Mar 5, 2026Locations: 2
Eligibility criteria
Have a full understanding of the study content, process, and possible adverse re... [+4]
Patients with head and neck tumor who are indicated for locoregional radical tre... [+21]